Avecho Biotechnology Limited (AU:AVE) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avecho Biotechnology Limited has announced the appointment of Kathy Connell as a Non-Executive Director, bringing her extensive experience in healthcare and biotechnology to the company’s board. Connell’s background includes impactful roles at Johnson & Johnson and Sanofi, where she executed deals worth over $US1B, and her leadership has been recognized with awards such as the BioMelbourne Network’s Woman of the Year. Her expertise is expected to be valuable as Avecho advances into a critical phase of clinical trials and seeks to secure lucrative licensing agreements for its proprietary drug delivery system, TPM.
For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.
